BioCryst
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
4505 Emperor Blvd Ste 200, Durham, North...Phone Number
(919) 859-1302Website
www.biocryst.comRevenue
$940.6 MillionStock Symbol
BCRXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About BioCryst
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.Explore more
BioCryst Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioCryst your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioCryst had a recent Job posting/layoffs
Funding: Get notified immidiatlly once BioCryst has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioCryst
Check if BioCryst has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on BioCryst recently announced quarterly report
BioCryst, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BioCryst launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BioCryst is spiking on competitors!
Recommended Actions
Find VP level buyers at BioCryst
Find 2 more new buyers
Compare Similar Companies to BioCryst
Compare insights from companies similar to BioCryst, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioCryst is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioCryst is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioCryst.
BioCryst financials insights
Gather financial insights about BioCryst, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Grant
$4.1M
Grant
$2.4M
2016
Debt
$23M
2018
Grant
$3.5M
2019
Debt
$100M
Stock Offering
$63M
2021
Other Financing Round
$350M
2023
Debt
$450M
BioCryst Tech Stack
A closer look at the technologies used by BioCryst
See more technologies
Most Recent Scoops
Person-Based
Earnings, Business Development, Corporate Strategy, Finance
Partnership
BioCryst has partnered with CareMed as the sole-source specialty pharmacy for ORLADEYO shipments to patients, with all ORLADEYO pellet prescriptions for pediatric patients currently shipping from CareMed and the 12-and-older population transitioning to CareMed over the course of the current month.
Partnership
Earnings
BioCryst has improved its non-GAAP operating cost guidance for the remainder of the year to a range of $420 million to $440 million, reduced from the prior range of $454 million to $470 million, driven by the shift to an external innovation R&D model and the planned closure of its Birmingham facility.
Financial Planning, Shut Down, Business Finance, Finance, Financial Strategy
Project
BioCryst has announced that ORLADEYO oral pellets have begun shipping to pediatric patients, with 47 prescriptions received through July 31, surpassing the total volume originally expected for all of 2026.
Pharmaceuticals
Person-Based
Finance, Risk
BioCryst News & Media
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan —BioCryst Pharmaceuticals Q2 Earnings Call Highlights
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. President and CEO Charlie GaBioCryst Reports Second Quarter 2026 Financial Results
— Total net revenue of $218.3 million and ORLADEYO® net revenue of $158.2 million —BioCryst to Report Second Quarter 2026 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioCryst
Sign Up For FreeTo access detailed company insights
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.... Read More
